Table 1.

Drugs that have shown the ability to rescue cisplatin or cetuximab resistance

Therapy	Agent	CAS RN	Downstream Effector	Ref
Cisplatin	Decitabine	2353-33-5	Gene methylation	[46]
Cisplatin	LY2109761	700874-71-1	TGFβRII	[47]
Cisplatin	LY364947	396129-53-6	TGFβRI in HPV-negative cells	[48]
Cisplatin	NG-amino-L-arginine	1031799-40-2	Nitrous oxide synthases	[49]
Cisplatin	EGF	62253-63-8	EGFR	[50]
Cetuximab	JQ1	1268524-70-4	BET protein family	[20]
Cetuximab	Apigenin	520-36-5	ERK1/2	[23]
Cetuximab	Barasertib	722543-31-9	AURKB	[23]
Cetuximab	Afatinib	439081-18-2	EGFR, HER2, HER4	[43]
Cetuximab	PKI-587	1197160-78-3	PI3K and mTOR	[51]
Cetuximab	Dorsomorphin	866405-64-3	AMPK	[52]
Cetuximab	Oxamate	565-73-1	Lactate dehydrogenase A	[53]
Cetuximab	Dichloroacetic acid	79-43-6	Pyruvate dehydrogenase kinase-1	[54]
Cetuximab	Bortezomib	179324-69-7	NF-κB	[55]
Cetuximab	Parthenolide	20554-84-1	NF-κB	[55]
Cetuximab	Dasatinib	302962-49-8	Src family kinase	[56]
Cetuximab	R428	1037624-75-1	AXL	[57]
Cetuximab	PPY-A	875634-01-8	c-ABL kinase	[57]
Cetuximab	R763	871357-89-0	Aurora kinases	[58]
Cetuximab	TAK242	243984-11-4	Toll-like receptor 4	[59]
Cetuximab	MEHD7945A	unknown	EGFR and HER3	[60]

The Chemical Abstracts Service Registry Number is included (CAS RN) is included for identification purposes. TGFβR = transforming growth factor β receptor; HPV = human papillomavirus; BET = bromodomain and extra terminal; mTOR = mammalian target of rapamycin; AMPK = 5’-adenosine monophosphate-activated protein kinase.